Evidence map›Paper›PMID 33977495›Full record

ReviewAdvances in therapy2021

Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.

Jamy Ard, Angela Fitch, Sharon Fruh, Lawrence Herman

2 registry-linked trialsOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 143 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 11 pooled it
22.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07513168 phase4recruitingstarted 2025, after this paper: background citation

Efficacy and Safety of Low-Dose Semaglutide for Weight Loss and Cardiometabolic Improvement in Obese Pakistani Adults Without Type 2 Diabetes: A Single-Arm Open-Label Single-Center Trial

Ran2025Enrolled60Registered outcomes6Posted comparisons0ConditionsCardiometabolic Risk Factors, Obesity, Weight ReductionArmsLocally available low-dose semaglutide (0.25 mg, 0.5 mg, 1 mg)
PMID 33755728PMID 33625476PMID 38679221PMID 36216945PMID 36578889PMID 38017205PMID 38740993PMID 38851997PMID 38976257PMID 40196933PMID 40804463PMID 31689026other papers from this trial
Open the trial in the graph
NCT07617155 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence: Protocol for a Randomized Clinical Trial

TypeinterventionalSponsorPeking Union Medical College HospitalRan2026 to 2028Enrolled396ConditionsHypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis, Pancreatitis Relapsing, HypertriglyceridemiaArmsSemaglutide, Placebo (Normal Saline)
3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 11 syntheses or guidelines pooled it, 266 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.The Journal of clinical endocrinology and metabolism · 2022 · on this map
    Trial
  19. Trial
  20. Trial

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Jamy ArdDivision of Public Health Sciences, Department of Epidemiology and Prevention, Wake Forest University School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC, 27157, USA. jard@wakehealth.edu.ORCID http://orcid.org/0000-0002-1643-6795
Angela FitchMGH Weight Center, Massachusetts General Hospital, Boston, MA, USA.
Sharon FruhCollege of Nursing, University of South Alabama, Mobile, AL, USA.
Lawrence HermanDoctor of Medical Science Program, University of Lynchburg, Lynchburg, VA, USA.
Harvard University · USUniversity of Lynchburg · USUniversity of South Alabama · USWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is a chronic disease associated with many complications. Weight loss of 5-15% can improve many obesity-related complications. Despite the benefits of weight reduction, there are many challenges in losing weight and maintaining long-term weight loss. Pharmacotherapy can help people with obesity achieve and maintain their target weight loss, thereby reducing the risk of obesity-related complications. The prevalence of obesity in the USA has been increasing over the past few decades, and despite the availability of approved anti-obesity medications (AOMs), people with obesity may not be accessing or receiving treatment at levels consistent with the disease prevalence. Reasons for low levels of initiation and long-term use of AOMs may include reluctance of public health and medical organizations to recognize obesity as a disease, lack of reimbursement, provider inexperience, and misperceptions about the efficacy and safety of available treatments. This article aims to inform primary care providers about the mechanism of action of one class of AOMs, glucagon-like peptide 1 receptor agonists (GLP-1RAs), in weight loss and longer-term maintenance of weight loss, and the efficacy and safety of this treatment class. GLP-1RA therapy was initially developed to treat type 2 diabetes. Owing to their effectiveness in reducing body weight, once-daily subcutaneous administration of liraglutide 3.0 mg has been approved, and once-weekly subcutaneous administration of semaglutide 2.4 mg is being investigated in phase III trials, for obesity management. Considerations regarding adverse effects and contraindications for different drug classes are provided to help guide treatment decision-making when considering pharmacotherapy for weight management in patients with obesity.

Indexed as

Diabetes Mellitus, Type 2Pharmaceutical PreparationsGlucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesHumansHypoglycemic AgentsLiraglutideWeight LossGlucagon-Like Peptide-1 ReceptorGlucagon-Like PeptidesHypoglycemic AgentsLiraglutidePharmaceutical PreparationsAntiobesity medicationGlucagon-like peptide 1 receptor agonistObesityPharmacotherapyWeight loss

Identifiers

PMID33977495
PMCPMC8189979
OpenAlexW3163721607

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.